Gleamer vs HeartFlow
A cardiology program with CT scanners and coronary CTA volume buys Heartflow, and an emergency department or orthopedic imaging service buys Gleamer's BoneView. Heartflow computes fractional flow reserve from the angiogram in the vendor's cloud and charges per study, a pay-per-use model per its FY2025 10-K. The same 10-K reports $176.0M of 2025 revenue, 98% of it from FFRct, and the company trades on Nasdaq as HTFL.
BoneView reads X-rays for fractures, dislocations, bone lesions and effusions in adults and children over 2, and holds K212365 (March 2022) and K222176 (March 2023). RadNet announced the acquisition of Gleamer in March 2026 for up to EUR 230M, and Gleamer's site now says it is part of DeepHealth. Gleamer takes demo requests for pricing.
Radiology · Reviewed November 2, 2026
When to pick each one
Gleamer
- BoneView X-ray fracture and dislocation reads
- Adults and children over 2
- Acquired by RadNet in March 2026
HeartFlow
- FFRct and plaque analysis from coronary CTA
- Pay-per-use model per its 10-K
- Public on Nasdaq as HTFL
Score
Each row shows points earned of points available under the published rubric.
Gleamer
56of 100
HeartFlow
66of 100
| Dimension | Gleamer | HeartFlow | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 18.2 / 18.2 | 12.7 / 18.2 | +5.5 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 7.8 / 7.8 | -7.8 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 6 / 6 | -6 |
Scroll horizontally to see every column.
Pricing
Gleamer
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Demo request only. |
HeartFlow
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Per study | n/a | n/a | No public list price. The 10-K describes revenue as pay-per-use. |
Evidence
Gleamer
FDA decisions
K252486 (opens in new tab)510(k)2026-09-09
ChestView US (1.1)
K241620 (opens in new tab)510(k)2025-02-27
ChestView US
K241593 (opens in new tab)510(k)2025-02-05
BoneMetrics (US)
K213253 (opens in new tab)510(k)2023-06-30
Pixyl.Neuro
K222176 (opens in new tab)510(k)2023-03-02
BoneView
Show 1 more
K212365 (opens in new tab)510(k)2022-03-01
BoneView
Peer-reviewed
5 PubMed records name Gleamer.
- Opinion paper: artificial intelligence as a clinical ally in lung cancer detection-the case for Gleamer's ChestView. (opens in new tab)
- AI model for automatic spinopelvic and spinal alignment parameters measurement from EOS. (opens in new tab)
- Fracture Detection on Bone Radiographs: The Impact of an AI Tool on Orthopaedic Night Shifts. (opens in new tab)
HeartFlow
FDA decisions
K250902 (opens in new tab)510(k)2025-07-18
HeartFlow Analysis
K213857 (opens in new tab)510(k)2022-10-14
HeartFlow Analysis
K203329 (opens in new tab)510(k)2021-01-08
HeartFlow Analysis
K190925 (opens in new tab)510(k)2019-08-15
K182035 (opens in new tab)510(k)2018-12-06
Show 3 more
K161772 (opens in new tab)510(k)2016-08-24
K152733 (opens in new tab)510(k)2016-01-13
DEN130045 (opens in new tab)De Novo2014-11-26
FFRct
Peer-reviewed
2 PubMed records name HeartFlow.
- Prognostic value of CT-derived fractional flow reserve for major adverse cardiovascular events in patients with suspected or known coronary artery disease: a systematic review and meta-analysis. (opens in new tab)
- Diagnostic Performance of AI-enabled Plaque Quantification from Coronary CT Angiography Compared with Intravascular Ultrasound. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Gleamer | HeartFlow |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | 2007 |
| HQ | FR | US |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.